Accrued Expenses

3 Months Ended

Mar. 31, 2019

7.	ACCRUED EXPENSES

Accrued expenses consisted of the following:

	March 31, 2019		December 31, 2018
Accrued clinical operations and trials costs	$	9,585,065	$	4,914,881
Accrued product development costs		3,703,548		2,222,093
Accrued compensation		1,327,756		2,253,621
Accrued other		947,484		460,596
Total	$	15,563,853	$	9,851,191